Track market-moving stories before they get noisy

Key Takeaways Abbott added Cologuard, Oncotype DX, Oncodetect and Cancerguard via the Exact Sciences deal.Abbott presented new cancer detection data and CRC screening findings at major 2026 meetings.Abbott expects about $3 billion in incremental 2026 sales from the Exact Sciences acquisition. Abbott’s (ABT - Free Report) $23 billion acquisition of Exact Sciences was among the headline MedTech M&A deals of 2025, according to a J.P Morgan report. Following the close, the company gained a broad portfolio and differentiated pipeline aimed at early detection of cancer and personalized treatment decisions. This includes Cologuard, a non-invasive colorectal cancer screening (CRC) option, Oncotype DX for early-stage breast cancer planning, the Oncodetect tumor-informed molecular residual disease (MRD) test and the Cancerguard multi-cancer early detection (MCED) blood test.

The transaction also added a new growth vertical to Abbott's already high-single-digit growth profile, positioning it at the forefront of the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. In recent months, Abbott has continued to showcase the expanding evidence base of its Cancer Diagnostics portfolio, supporting its strength and potential.

During the Digestive Disease Week (“DDW”) 2026 in Chicago, the company shared new data highlighting the potential of emerging liver and esophageal tests. CRC screening data presented at DDW further bolsters the effectiveness of Cologuard in driving better outcomes and getting more people screened.

At the American Association for Cancer Research Annual Meeting 2026, the company reported advancements in its multi-biomarker, MCED program supporting the commercially available Cancerguard test.  Data showed that combining methylation and protein biomarkers improves cancer detection across stages, with each biomarker independently contributing to overall performance. 

Another positive development came when the American Cancer Society updated its CRC screening guidelines, reaffirming Cologuardand Cologuard Plusas preferred non-invasive screening options for average-risk adults aged 45 and older. Both tests are used at a three-year interval.

From a financial standpoint, Abbott projects the Exact Sciences deal to add roughly $3 billion of incremental sales in 2026. That said, the adjusted EPS guidance of $5.38-$5.58 incorporates about $0.20 of dilution tied to the transaction.

M&A Activity Among Abbott’s PeersMedtronic (MDT - Free Report) recently announced its intent to acquire SPR Therapeutics, Inc., a privately held company specializing in temporary, percutaneous peripheral nerve stimulation therapies for chronic pain management. The planned acquisition will enhance Medtronic's Neuromodulation portfolio, increasing its ability to reach more people with complementary, minimally invasive pain relief options earlier in their care continuum. In April 2026, the company acquired CathWorks, significantly boosting its interventional cardiology portfolio.

In May 2026, Stryker (SYK - Free Report) completed the acquisition of Amplitude Vascular Systems, Inc., a privately held company developing a next-generation intravascular lithotripsy (IVL) platform to treat complex peripheral arterial disease. The addition of an IVL platform is expected to bolster Stryker’s impact on peripheral vascular solutions.

The Zacks Rundown for ABT StockOver the past six months, ABT shares have plunged 26% compared with the industry’s 28.1% decline. 

Image Source: Zacks Investment Research

Abbott is trading at a forward, three-year Price/Sales (P/S) of 3.03X, lower than its 4.54X median but above the industry average of 2.06X.

Image Source: Zacks Investment Research

Take a look at how estimates for Abbott’s 2026 and 2027 earnings are shaping up. 

Image Source: Zacks Investment Research

Abbott currently carries a Zacks Rank #4 (Sell).  

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals despite recent negative price action. ABT trades at a 17.1% P/E and 35.1% sales multiple discount to peers, with DCF fair value estimates implying 21.8–39.4% upside. Growth is underpinned by the Exact Sciences acquisition, diagnostics megatrends, and global expansion in CGM, with FY26 guidance raised for both sales and EPS.

Abbott declares 410th consecutive quarterly dividend PR Newswire

ABBOTT PARK, Ill., June 12, 2026

, /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.

This marks the 410th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

View original content:https://www.prnewswire.com/news-releases/abbott-declares-410th-consecutive-quarterly-dividend-302799345.html

SOURCE Abbott

-

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in New York City.

The format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a Q&A session.

The live webcast of the presentation can be accessed via the Investors section of our website, https://ir.thermofisher.com. A replay of the webcast will be available following the presentation.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

More News From Thermo Fisher Scientific Inc.

Back to Newsroom

On May 04, 2026, we present a detailed DCF analysis for Thermo Fisher Scientific Inc TMO , a company that has experienced a price decline of 18.9% year-to-date, despite a 12.2% increase over the past year. This analysis will explore the intrinsic value of TMO based on both earnings and free cash flow models, providing insights into its current valuation status.

DCF Earnings-based intrinsic value of $477.60 vs current price of $469.21 (margin of safety: 1.8%) DCF FCF-based intrinsic value of $333.59 vs current price (second opinion: modestly overvalued) GF Score™ of 87/100 indicates high reliability of the DCF inputs What Is TMO Worth? DCF Earnings-Based Model The DCF earnings-based model for TMO utilizes a two-stage approach to estimate the intrinsic value of the stock. The first stage considers a high growth phase over the next ten years, while the second stage accounts for a terminal growth phase. Below are the assumptions used in this model:

Parameter Value Current EPS (TTM, excl. non-recurring) $23.16 10-Year Growth Rate 13.8% 10-Year Treasury Rate 4.37% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The growth phase (Years 1-10) assumes an annual EPS growth of 13.8%, which is then discounted at a rate of 11%. The terminal phase (Years 11-20) assumes a slowdown to a 4% growth rate, also discounted at 11%. The calculation summary is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 13.8%, discounted at 11% $266.29 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $211.31 Intrinsic Value Growth + Terminal $477.60 Comparing the current price of $469.21 with the intrinsic value of $477.60 indicates that TMO is fairly valued, with a margin of safety of 1.8%. It's important to note that GuruFocus uses EPS excluding non-recurring items, as research shows stock prices correlate more closely with earnings than free cash flow. For further calculations, visit the TMO DCF Calculator.

What Does the Free Cash Flow DCF Say? The free cash flow (FCF) based intrinsic value for TMO is calculated at $333.59. When comparing this to the earnings-based intrinsic value of $477.60, there is a significant discrepancy. The FCF model suggests that TMO is modestly overvalued, with a margin of safety of -40.6%. This divergence highlights the importance of considering multiple valuation perspectives when assessing a stock's worth.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for TMO is calculated at $577.76, providing a third perspective on the company's valuation. GF Value™ is GuruFocus' proprietary measure that takes into account historical trading multiples, past business growth, and future performance estimates. While the earnings-based DCF suggests fair valuation, the FCF model indicates modest overvaluation, and the GF Value™ suggests that TMO is undervalued. This divergence among the three models underscores the complexity of valuation assessments. For more information, visit the GF Value™ page.

What Does TMO's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021). Below is the breakdown of TMO's GF Score™:

Metric Rating GF Score™ 87/100 Financial Strength 5/10 Profitability 8/10 Growth 7/10 Valuation 8/10 Momentum 7/10 With a predictability rank of 0/5 stars, TMO's DCF model is less reliable, indicating that investors should exercise caution when relying solely on this analysis. For more details, visit the TMO stock page.

Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to growth rate and discount rate assumptions. Stocks with low predictability ratings, such as TMO, produce less reliable DCF estimates. Additionally, the terminal growth rate of 4% is a simplifying assumption that may not reflect actual future performance.

What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—the consensus indicates that TMO is fairly valued based on the earnings model, modestly overvalued according to the FCF model, and undervalued from the GF Value™ perspective. Overall, investors should consider these varied insights before making investment decisions. For the full DCF analysis, visit the TMO DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is TMO's intrinsic value based on DCF?

According to the DCF analysis, the earnings-based intrinsic value is $477.60, while the FCF-based intrinsic value is $333.59.

Is TMO overvalued or undervalued?

The DCF earnings model suggests TMO is fairly valued, while the FCF model indicates it is modestly overvalued. The GF Value™ suggests it is undervalued.

How reliable is the DCF model for TMO?

The predictability rank for TMO is 0/5 stars, indicating that the DCF model may not be very reliable for this stock.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Have you evaluated the performance of Thermo Fisher Scientific's (TMO - Free Report) international operations during the quarter that concluded in March 2026? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

While delving into TMO's performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street.

The company's total revenue for the quarter amounted to $11.01 billion, showing rise of 6.2%. We will now explore the breakdown of TMO's overseas revenue to assess the impact of its international operations.

Unveiling Trends in TMO's International RevenuesOther regions generated $372 million in revenues for the company in the last quarter, constituting 3.4% of the total. This represented a surprise of -1.48% compared to the $377.57 million projected by Wall Street analysts. Comparatively, in the previous quarter, Other regions accounted for $462 million (3.8%), and in the year-ago quarter, it contributed $337 million (3.3%) to the total revenue.

During the quarter, Asia-Pacific contributed $1.97 billion in revenue, making up 17.9% of the total revenue. When compared to the consensus estimate of $1.94 billion, this meant a surprise of +1.44%. Looking back, Asia-Pacific contributed $2.28 billion, or 18.6%, in the previous quarter, and $1.89 billion, or 18.3%, in the same quarter of the previous year.

Of the total revenue, $2.96 billion came from Europe during the last fiscal quarter, accounting for 26.9%. This represented a surprise of +4.76% as analysts had expected the region to contribute $2.82 billion to the total revenue. In comparison, the region contributed $3.37 billion, or 27.6%, and $2.62 billion, or 25.3%, to total revenue in the previous and year-ago quarters, respectively.

International Market Revenue ProjectionsWall Street analysts expect Thermo Fisher to report $11.61 billion in total revenue for the current fiscal quarter, indicating an increase of 7% from the year-ago quarter. Other regions, Asia-Pacific and Europe are expected to contribute 3.5% (translating to $405.2 million), 18% ($2.08 billion), and 26.1% ($3.03 billion) to the total revenue, respectively.

For the full year, the company is expected to generate $47.5 billion in total revenue, up 6.6% from the previous year. Revenues from Other regions, Asia-Pacific and Europe are expected to constitute 3.4% ($1.63 billion), 17.6% ($8.36 billion) and 25.6% ($12.15 billion) of the total, respectively.

Concluding RemarksThermo Fisher's reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.

Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.

Thermo Fisher, bearing a Zacks Rank #3 (Hold), is expected to mirror the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Exploring Recent Trends in Stock PriceOver the preceding four weeks, the stock's value has diminished by 4.5%, against an upturn of 10% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Thermo Fisher among its entities, has depreciated by 0.9%. Over the past three months, the company's shares have seen a decline of 13.6% versus the S&P 500's 4.4% increase. The sector overall has witnessed a decline of 8.1% over the same period.

On May 11, 2026, we present a discounted cash flow (DCF) analysis for Thermo Fisher Scientific Inc TMO . The company has experienced a challenging price performance recently, with a year-to-date decline of 19.7%, despite a 13.6% increase over the past year. Below are key highlights from our analysis:

DCF Earnings-based intrinsic value of $477.60 compared to the current price of $465.00 (margin of safety: 2.6%) DCF Free Cash Flow (FCF)-based intrinsic value of $333.59, suggesting a second opinion on valuation GF Score™ of 87/100 indicates a strong reliability of the DCF inputs What Is TMO Worth? DCF Earnings-Based Model In our DCF earnings-based model, we assume a current earnings per share (EPS) of $23.16, with a projected growth rate of 13.8% over the next ten years. The discount rate is set at 11%, which is derived from the risk-free rate and equity risk premium. After the growth phase, we apply a terminal growth rate of 4% for the following ten years. Below is a summary of the key assumptions:

Parameter Value Current EPS (TTM, excl. non-recurring) $23.16 10-Year Growth Rate 13.8% 10-Year Treasury Rate 4.33% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The two-stage model consists of a growth phase for the first ten years, followed by a terminal phase. The calculation summary is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 13.8%, discounted at 11% $266.29 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $211.31 Intrinsic Value Growth + Terminal $477.60 The current price of $465.00 is compared to the intrinsic value of $477.60, indicating that the stock is fairly valued with a margin of safety of 2.6%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For further details, visit the TMO DCF Calculator.

What Does the Free Cash Flow DCF Say? The intrinsic value based on the Free Cash Flow (FCF) model is calculated at $333.59. When comparing this with the earnings-based intrinsic value of $477.60, we see a significant discrepancy. The FCF model suggests that TMO is modestly overvalued, with a margin of safety of -39.4%.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Thermo Fisher Scientific Inc is calculated at $576.75, providing a third perspective on valuation. GF Value™ is GuruFocus' proprietary measure that considers historical trading multiples, past business growth, and future performance estimates. The three models present differing views: the earnings-based DCF suggests fair valuation, the FCF-based model indicates modest overvaluation, while GF Value™ suggests that the stock is undervalued. For more insights, visit the GF Value™ page.

What Does TMO's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested from 2006 to 2021). Below is a summary of TMO's GF Score™ metrics:

Metric Rating GF Score™ 87/100 Financial Strength 5/10 Profitability 8/10 Growth 7/10 Valuation 8/10 Momentum 8/10 With a predictability rating of 0/5 stars, it is important to note that higher predictability ratings generally lead to more reliable DCF estimates for stocks. For additional information, visit the TMO stock page.

Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to assumptions regarding growth rates and discount rates. Stocks with low predictability ratings, such as TMO's 0/5 stars, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect actual future performance.

What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find that TMO presents a mixed picture. While the earnings-based DCF suggests fair valuation, the FCF model indicates modest overvaluation, and the GF Value™ suggests undervaluation. Overall, the consensus leans towards TMO being fairly valued at this time. For the full DCF analysis, visit the TMO DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is TMO's intrinsic value based on DCF?

[Answer: earnings-based $477.60, FCF-based $333.59]

Is TMO overvalued or undervalued?

[Answer using DCF + GF Value™ consensus]

How reliable is the DCF model for TMO?

[Answer using predictability rank 0/5]

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

-

The state-of-the-art facility enhances support for complex modalities across all phases of drug development

Key facts

Thermo Fisher opens new bioanalytical and biomarker laboratory in Gothenburg, Sweden Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions Supports pharmaceutical and biotechnology customers across all phases of drug development Helps customers globally accelerate innovation and bring new therapies to patients faster WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development.

With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker services across the full drug development lifecycle, from preclinical studies through post-approval. Its advanced technology suite includes cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics, supporting both small molecules and complex therapeutic modalities such as peptides, antibodies, oligonucleotides, and cell and gene therapies.

“Our new Gothenburg laboratory is purpose-built to address the evolving needs of modern drug development, particularly as therapies become more complex and data requirements increase,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “By investing in advanced capabilities and strategic locations, such as Gothenburg, we are helping our customers in Europe and globally accelerate innovation and bring new therapies to patients faster.”

Thermo Fisher Scientific's PPD™ Laboratory services support clinical trials at all levels and offers integrated support through its network of bioanalytical, biomarker, GMP, vaccine sciences and central labs to enhance clinical trial and drug development efficiency. The new lab in Gothenburg complements the business’ other bioanalytical labs in Richmond, Virginia, and Suzhou, China, and it reinforces the company’s long-term commitment to the Swedish life sciences ecosystem and continued growth as a major employer and investor in the region.

Frequently Asked Questions

What does the new lab add to the life sciences industry?

The lab in Gothenburg, Sweden, expands the company’s global bioanalytical capabilities to support global pharmaceutical and biotechnology customers across all phases of drug development. Who is it designed for?

The new lab strengthens support for pharmaceutical and biotechnology customers across all phases of drug development. What problem does it solve?

The facility enhances Thermo Fisher Scientific’s ability to deliver rapid, reliable bioanalytical services from preclinical development through post-approval studies, helping customers accelerate innovation and bring new therapies to patients faster. Why does it matter?

The lab complements Thermo Fisher's existing bioanalytical laboratories in the U.S. and China while reinforcing Thermo Fisher Scientific’s long-term commitment to the Swedish life sciences ecosystem, supporting regional growth, employment, and investment. About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

More News From Thermo Fisher

Back to Newsroom

-

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

More News From Thermo Fisher Scientific Inc.

Back to Newsroom

On May 26, 2026, we present a DCF analysis for Thermo Fisher Scientific Inc TMO . The stock has experienced a mixed performance recently, with a year-to-date decline of 22.6%, while showing a 12.3% increase over the past year.

DCF Earnings-based intrinsic value of $477.60 vs current price of $448.28 (margin of safety: 6.1%) DCF FCF-based intrinsic value of $333.59 vs current price (second opinion: modestly overvalued) GF Score™ of 85/100 indicates strong reliability of the DCF inputs What Is TMO Worth? DCF Earnings-Based Model To determine the intrinsic value of Thermo Fisher Scientific Inc, we utilize a two-stage DCF model. The first stage considers a growth phase where earnings per share (EPS) is expected to grow at a rate of 13.8% annually for the next 10 years. The second stage accounts for a terminal growth rate of 4% for the subsequent 10 years. The discount rate applied is 11%, which is derived from the risk-free rate and equity risk premium.

Parameter Value Current EPS (TTM, excl. non-recurring) $23.16 10-Year Growth Rate 13.8% 10-Year Treasury Rate 4.48% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the DCF model is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 13.8%, discounted at 11% $266.29 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $211.31 Intrinsic Value Growth + Terminal $477.60 The current price of TMO is $448.28, which indicates that the stock is fairly valued with a margin of safety of 6.1%. It is important to note that GuruFocus uses EPS without non-recurring items because research shows stock prices correlate more closely with earnings than free cash flow. For more details, visit the TMO DCF Calculator.

What Does the Free Cash Flow DCF Say? In addition to the earnings-based DCF model, we also consider the free cash flow (FCF) DCF model, which yields an intrinsic value of $333.59. This valuation is significantly lower than the earnings-based intrinsic value of $477.60, suggesting a divergence in the two models. The FCF-based model indicates that TMO is modestly overvalued with a margin of safety of -34.4%.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Thermo Fisher Scientific Inc is $578.87, which suggests that the stock is undervalued by 22.6%. GF Value™ is GuruFocus' proprietary measure calculated from historical trading multiples, past business growth, and future performance estimates. While the earnings-based DCF model suggests fair valuation, the FCF model indicates modest overvaluation, and the GF Value™ presents a third perspective of undervaluation. For further insights, visit the GF Value™ page.

What Does TMO's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).

Metric Rating GF Score™ 85/100 Financial Strength 5/10 Profitability 8/10 Growth 7/10 Valuation 8/10 Momentum 7/10 With a predictability rank of 0/5 stars, it indicates that the DCF model may be less reliable for this stock. For more information, visit the TMO stock page.

Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to growth rate and discount rate assumptions. Stocks with low predictability ratings, such as TMO, produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect future market conditions accurately.

What This Means for Investors In summary, the DCF earnings model suggests that TMO is fairly valued at $477.60, while the FCF model indicates it is modestly overvalued at $333.59. The GF Value™ further suggests that the stock is undervalued at $578.87. Overall, the consensus points towards a fair valuation of TMO. For the full DCF analysis, visit the TMO DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is TMO's intrinsic value based on DCF?

Answer: earnings-based $477.60, FCF-based $333.59

Is TMO overvalued or undervalued?

Answer: The earnings-based DCF suggests fair valuation, while the FCF model indicates modest overvaluation; GF Value™ suggests undervaluation.

How reliable is the DCF model for TMO?

Answer: The predictability rank is 0/5, indicating less reliability of the DCF model for this stock.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

On May 28, 2026, Thermo Fisher Scientific Inc TMO shares rose 6.8% today, now trading at $487.22. The stock's performance remains volatile with a 52-week range between $385.46 and $643.99.

GF Value™ verdict: Current price of $487.22 is 15.9% below GF Value™ of $579.15. GF Score™ of 83/100 indicates a strong overall rating. Notable signal: Insiders sold $8.1M worth of shares in the last 3 months, indicating potential caution. Is TMO Overvalued or Undervalued? With a current price of $487.22 and a GF Value™ of $579.15, Thermo Fisher Scientific Inc is considered 15.9% undervalued, suggesting a potential opportunity for investors. The GF Valuation label indicates that the stock is modestly undervalued, presenting a margin of safety for those considering entry. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the undervaluation may present an attractive entry point, the recent trend of insider selling could be a signal of caution. It’s essential for investors to weigh this against the favorable GF Value™ assessment, as it suggests there may be underlying factors influencing the stock's performance that could impact future growth or stability.

How Does TMO's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 26.8x 31.3x Forward P/E 19.6x N/A The current P/E ratio of 26.8x is significantly below its 5-year median P/E of 31.3x, implying that the stock is trading at a discount relative to its historical valuation. This aligns with the GF Value™ verdict that suggests the stock is undervalued, reinforcing the opportunity indicated by the current price.

What Does TMO's GF Score™ Tell Us? Metric Rating GF Score™ 83/100 Financial Strength 5/10 Profitability 8/10 Growth 7/10 Valuation 8/10 Momentum 5/10 The GF Score™ of 83/100 highlights Thermo Fisher Scientific Inc’s strong performance in profitability and valuation, both rated at 8/10. However, the financial strength rating of 5/10 suggests some caution regarding the company’s balance sheet. Overall, the scores indicate a solid investment prospect, but the weaker financial strength may warrant a closer examination of the company's operational stability.

What Are Insiders Doing with TMO Stock? In recent months, insiders have sold $8.1 million worth of Thermo Fisher shares, with no reported buying activity. This pattern of insider selling might imply that those closest to the company are cautious about its near-term prospects, which can be a red flag for potential investors. However, it is important to consider that insider activity can be influenced by various personal financial strategies and not necessarily reflect the company's overall performance.

What This Means for Investors Based on the analysis of GF Value™, Thermo Fisher Scientific Inc appears to be undervalued at the current price of $487.22. While the stock presents an attractive entry point given its undervaluation, the insider selling may indicate some caution, prompting a careful approach moving forward.

For the complete analysis, visit the Thermo Fisher Scientific Inc TMO stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is TMO's GF Score™?

TMO's GF Score™ is 83/100, indicating a strong overall rating based on multiple financial metrics.

Is TMO overvalued or undervalued?

TMO is currently undervalued with a GF Value™ of $579.15, suggesting a potential upside based on its intrinsic value.

What is TMO's P/E ratio?

The current P/E ratio is 26.8x, which is below its 5-year median P/E of 31.3x, indicating that the stock is trading at a discount compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

New Orbitrap platforms, AI-enabled software and integrated workflows deliver deeper insight, more confident development decisions and stronger results across complex scientific markets

New Orbitrap Mass Spectrometer Platforms: Thermo Fisher Scientific is introducing three new Thermo Scientific™ Orbitrap™ platforms at ASMS 2026, bringing high-resolution mass spectrometry and end-to-end solutions to more decision points across research, biopharmaceutical and applied markets. AI-Enabled Technology for Faster Interpretation: New software capabilities, including Thermo Scientific™ Proteoform Studio, Thermo Scientific™ Proteome Discoverer™ 3.4, Thermo Scientific™ BioPharma Finder™ 5.5 and the acquisitions of MSAID and Proteinaceous, help laboratories speed proteomics analysis, spectral interpretation and advanced protein characterization. More Reliable Results for Regulated Contaminant Testing: New Orbitrap and targeted mass spectrometry workflows support environmental, water and food safety laboratories with high-resolution screening and reliable quantitation for dioxins, persistent organic pollutants (POPs) and emerging contaminants. WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference.

Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that challenge by bringing its flagship Orbitrap technology to more scientific decision points. The company’s expanded portfolio combines the depth of high-resolution accurate-mass technology with end-to-end solutions, enabling laboratories to advance discoveries, accelerate the development of new medicines and ensure more confident testing for food, air and water.

“Orbitrap technology has long set the standard for breakthrough discovery, and customers now want that same confidence across applied scientific markets,” said Ronald Tabaksblat, president, chromatography and mass spectrometry, Thermo Fisher Scientific. “At ASMS 2026, we are showcasing how Thermo Fisher is scaling Orbitrap innovation through connected platforms, software and workflows that support advanced research, drug development and applied testing with decision-ready results.”

Clearer Disease Insights in Research

The new Thermo Scientific™ Orbitrap™ Tribrid™ Apex Mass Spectrometer (MS) gives researchers a more powerful way to study challenging samples on a single platform. As Thermo Fisher’s most versatile and highest-performing Orbitrap Tribrid, the Orbitrap Tribrid Apex MS brings multiple capabilities together in one system, including three mass analyzers, a new infrared laser option for alternative fragmentation and Thermo Scientific™ Direct Mass Technology™ Mode. Together, these features help researchers get clearer answers from complex biology earlier in the discovery process. Thermo Fisher also expanded its software capabilities across proteomics, spectral analysis and advanced protein characterization:

MSAID and Proteinaceous, Thermo Fisher’s recent software acquisitions, deliver smarter proteomics workflows that speed analysis and streamline connectivity. MSAID brings AI-driven proteomics and machine learning expertise, while Proteinaceous adds top-down and native mass spectrometry bioinformatics. Thermo Scientific™ Proteoform Studio Software provides researchers with a streamlined proteomics workflow from acquisition through reporting, including Direct Mass Technology analysis for deeper characterization. Thermo Scientific™ Proteome Discoverer™ 3.4 Software helps scientists manage more proteomics workflows in one place, making it easier to analyze additional data with greater flexibility, speed and coverage. Greater Confidence in Biopharma and Pharma Drug Development

Thermo Fisher unveiled the Thermo Scientific™ Orbitrap™ Excedion™ Mass Spectrometer an Orbitrap platform designed to reduce performance tradeoffs in drug development. Built for applications ranging from drug metabolism studies to oligonucleotide and peptide analysis, the Orbitrap Excedion MS offers enhanced dynamic range (eDR) that detects three to five times more compounds in complex samples and delivers more reproducible results across larger studies. For the first time, laboratories can upgrade to Orbitrap Excedion Pro MS without replacing their instrument, which expands their analytical power while minimizing cost and disruption to ongoing work.

Thermo Fisher also introduced complementary innovations that provide biopharmaceutical development labs with a ready-made, end-to-end workflow:

Thermo Scientific™ Vanquish™ Amplify UHPLC Systems use an inert, metal-free sample flow path engineered to minimize adsorption and secondary interactions, helping scientists analyze sensitive biological molecules, such as short oligos, with less sample loss, better reproducibility and greater confidence in results from method development through QC. Thermo Scientific™ SurePac™ RP MDi™ Columns are purpose-built for oligonucleotide, mRNA and protein therapeutic analysis, helping improve recovery, separation and reproducibility under demanding conditions. Thermo Scientific™ SMART Digest™ OligoSelect™ Kit simplifies sample preparation for oligonucleotide bioanalysis with a single, streamlined workflow that reduces time and cost. Thermo Scientific™ BioPharma Finder™ 5.5 Software helps scientists process complex top-down mass spectrometry data from the latest Thermo Fisher instruments faster while maintaining consistent results. As drugs move further through development, laboratories need robust workflows for regulated bioanalysis and QA/QC. For these later-stage needs, Thermo Fisher will also showcase the Thermo Scientific™ TSQ Certis™ Triple Quadrupole Mass Spectrometer. It helps scientists accelerate drug development by measuring samples 15% faster and running more than twice as long between maintenance events for complex matrices like plasma.

Regulatory-ready Results for Food and Environmental Safety

The Thermo Scientific™ Orbitrap Exploris™ GC S Mass Spectrometer is a high-resolution gas chromatography-mass spectrometry platform designed to modernize dioxin and persistent organic pollutants (POPs) analysis for environmental and food safety laboratories. As regulations evolve and contaminant lists expand, the Orbitrap Exploris GC S MS delivers regulatory-ready, ultra-trace results with the sensitivity and resolving power needed for confident, reliable testing. With more than twice the resolution of many existing systems, it also helps laboratories identify emerging contaminants without additional instruments, saving time and reducing complexity in high-stakes public health or environmental testing.

Thermo Fisher will also showcase the Thermo Scientific™ Orbitrap Exploris™ EFOX Mass Detector for high-resolution screening of PFAS, pesticides and related contaminants, alongside the Thermo Scientific™ TSQ Altis™ Plus EFOX Triple Quadrupole Mass Spectrometer for reliable, high-throughput quantitation. Together with application expertise and service, these systems help environmental, water and food safety laboratories detect known and emerging contaminants faster, respond to potential risks sooner and make more confident public health decisions.

For more information about the newest end-to-end mass spectrometry solutions available at ASMS, please visit www.thermofisher.com/ASMS.

Instruments are for general lab use only. Not for diagnostic purposes.

FAQs
What is Thermo Fisher Scientific announcing at ASMS 2026?
Thermo Fisher Scientific announced new Orbitrap mass spectrometry platforms, AI-enabled software and end-to-end workflows for research, biopharma and applied market scientists. The portfolio includes new solutions for complex biology research, drug development and environmental and food safety testing.

What are the key Orbitrap innovations highlighted at ASMS 2026?
The key Orbitrap innovations highlighted at ASMS 2026 are the Thermo Scientific™ Orbitrap Tribrid™ Apex Mass Spectrometer, the Thermo Scientific™ Orbitrap Excedion™ Mass Spectrometer and the Thermo Scientific™ Orbitrap Exploris™ GC S Mass Spectrometer. Thermo Fisher also showcased the Thermo Scientific™ TSQ Certis™ Triple Quadrupole Mass Spectrometer, Thermo Scientific™ Orbitrap Exploris™ EFOX Mass Detector and Thermo Scientific™ TSQ Altis™ Plus EFOX Triple Quadrupole Mass Spectrometer along with AI-enabled software and supporting workflow solutions for research, biopharma and applied testing.

How do these innovations help customers accelerate science and decision-making?
These innovations help customers reduce tradeoffs, simplify complex analysis and deliver clearer, more actionable results across research, drug development and environmental testing. They enable scientists to generate deeper biological insight, make more confident development decisions and deliver faster, regulatory-ready contaminant testing.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Eli Lilly LLY is adding another Alzheimer's bet, striking a collaboration and licensing deal with Swedish biotech AlzeCure Pharma that could be worth more than $1 billion.

Under the agreement, Lilly gets global rights to AlzeCure's preclinical Alzheimer's project, Alzstatin ACD680. The therapy is designed to target Aβ42, a harmful amyloid beta protein tied to the formation of amyloid plaques, which are widely linked to Alzheimer's disease pathology.

AlzeCure will receive $10 million upfront, along with potential development and commercial milestone payments. The total deal value could exceed $1 billion, excluding royalties, and AlzeCure is also eligible for tiered mid single digit royalties on future product sales.

the deal shows Lilly is still willing to build around Alzheimer's despite the clinical and regulatory risks in the space. The company already has major exposure to neuroscience, and ACD680 gives it another early stage shot at changing the amyloid pathway. The next thing to watch is whether the drug can move from preclinical testing into human studies.

A Mounjaro KwikPen injection pen is seen in front of the Eli Lilly logo displayed on a screen in this illustration photo in Athens, Greece, on March 1, 2026. (Photo by Nikos Pekiaridis/NurPhoto via Getty Images)

NurPhoto via Getty Images

This article was written and reviewed by Doug Nathman and his team at Trefis. For questions, email [email protected].

More than just a simple rise, the pharmaceutical company's stock has been re-evaluated due to a growth narrative that continues to expand.

Let us clarify what a 54% stock increase over nine months truly signifies for a corporation of Eli Lilly's (LLY) scale. This is not a mere rebound; it is a fundamental revaluation. While the S&P 500 achieved a commendable 15% return, LLY investors found themselves in an entirely different category, witnessing the company add hundreds of billions in market capitalization to reach a valuation exceeding $1 trillion.

Wall Street doubters have scrutinized this dramatic increase and deemed the stock’s valuation “irrational.” At first glance, it does seem excessive for a 148-year-old pharmaceutical behemoth to value itself like a trendy tech company from Silicon Valley.

But is it really irrational?

When a corporation of Lilly's magnitude demonstrates a 56% year-over-year revenue growth and converts that into a remarkable 47% operating margin, it is not an outlier. It represents a fundamental revaluation. Here's why the market's calculations may indeed be valid.

A Growth Rate From Another WorldIn its latest quarter, Lilly's revenue increased by 56% compared to the previous year. This number is impressive on its own, but the context enhances its significance. This is not merely a one-time spike. The company’s revenue growth has reached 47.4% over the past twelve months, a substantial acceleration from its impressive three-year average of 37.9%. One might question how a company of this size can report increasing speeds rather than slowing ones. The driving force is its incretin franchise, with combined sales of Mounjaro and Zepbound reaching $12.8 billion in a single quarter.

MORE FOR YOU

This expansion is also significantly profitable. Lilly’s operating margin now stands at 47.3%, a dramatic rise from its three-year average of 35.3%. The company is efficiently transforming its historical sales surge into profit at an extraordinary rate. This focus on high-quality, high-margin growth is the same disciplined engine that drives our High Quality (HQ) Portfolio, a 30-stock strategy built to capture such performance across the broader market.

The Upcoming Wave ArrivesWas this nine-month increase merely a reward for previous achievements? Wall Street was also looking ahead, and Lilly continuously provided more reasons for optimism. During this period, the company received a significant FDA approval for Foundayo, an oral medication for weight management. As CEO David Ricks pointed out, this marked “the first time a new incretin medication has been introduced with obesity as its primary indication.” It opens up a vast market opportunity, and Lilly is poised to lead with a convenient pill.

The company also engaged in a series of acquisitions, announcing deals to purchase several clinical-stage biotechs such as Orna Therapeutics and Centessa Pharmaceuticals to enhance its product pipeline for the future. The message was unmistakable: the ongoing influx of cash would be utilized to construct the next phase.

Yet, as the company launches new initiatives like Lilly Employer Connect to deliver its products to patients, it raises a critical question that looms over this narrative. The scientific advancements are impressive; however, the logistics present a different challenge.

Having demonstrated its ability to develop groundbreaking medications, can Lilly craft a business model that ensures widespread availability?

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of EBGLYSS (lebrikizumab-lbkz) for subcutaneous use in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis. EBGLYSS is already approved for a once-monthly maintenance dose, with long-term data showing durable disease control. Now, EBGLYSS gives patients with moderate-to-severe atopic dermatitis the option to manage their condition with as few as six maintenance injections per year.1

"Today's approval builds on EBGLYSS' established long-term durability, with a new option for one maintenance dose every eight weeks. For people living with moderate-to-severe atopic dermatitis, that means a treatment they only need to take as few as six times a year—without prescription topicals from the start," said Adrienne Brown, executive vice president and president of Lilly Immunology. "EBGLYSS now gives patients the opportunity to flare less and live their lives with fewer interruptions from atopic dermatitis."

The approval is based on longitudinal exposure-response modeling data and supported by every-eight-week clinical data from an extension to the Phase 3 ADjoin long-term trial, which evaluated EBGLYSS maintenance dosing every four weeks or every eight weeks over 32 weeks.2

"The option to extend EBGLYSS maintenance dosing to every eight weeks represents an important moment for patients living with moderate-to-severe atopic dermatitis," said Peter Lio, M.D., author of the ADjoin study and clinical assistant professor of dermatology and pediatrics, Northwestern University. "This new dosing regimen without mandatory topicals gives patients a new option to manage their condition based on individual needs. It's about meeting patients where they are in their lives."

No new safety signals were noted in the EBGLYSS safety data in the 32-week ADjoin Q8W extension. No patients discontinued due to adverse events through 32 weeks. The most common (≥1%) adverse reactions reported with EBGLYSS are conjunctivitis, injection site reactions and herpes zoster.1

"Living with moderate-to-severe atopic dermatitis often means dealing with a cycle of symptoms and time-intensive treatment routines during and in-between flares," said Kristin Belleson, president and CEO of the National Eczema Association. "Patients living with moderate-to-severe atopic dermatitis seek treatments that can offer durable disease control and fewer injections. This new option can ease the burden, allowing patients to spend less time thinking about managing their condition on a daily basis."

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe.

About the Q8W ADjoin Extension
The Q8W ADjoin extension (NCT04392154) evaluated EBGLYSS administered once every eight weeks (Q8W) and once every four weeks (Q4W), assessing its long-term safety and efficacy over 32 weeks in patients with moderate-to-severe atopic dermatitis across select countries. Adult and adolescent patients (ages 12–17, weighing ≥40 kg) who completed the 100-week ADjoin long-term study, including participants from the Phase 3 ADvocate 1 and 2 trials (52 weeks), ADore trial (52 weeks) and the ADopt-VA (16 weeks) trial, were eligible to enroll. Patients in this analysis received open-label EBGLYSS 250 mg, Q8W or Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose) or response at extension baseline. The approved maintenance dose of EBGLYSS is 250 mg every four weeks or 250 mg every eight weeks, after taking EBGLYSS 250 mg every two weeks for 16 weeks or later when adequate clinical response is achieved.

About EBGLYSS
EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.1,3,4 EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of atopic dermatitis, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.1

The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating more than 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin) and adolescent open-label (ADore) studies. The program also includes a study assessing the impact of EBGLYSS on vaccine immune response in adults (ADopt-VA). EBGLYSS has been studied in patients with skin of color (ADmirable) and in dupilumab-experienced patients (ADapt).

EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment, administered with or without topical corticosteroids, that offers every-four-week or every-eight-week maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well-controlled with topical prescription therapies.1  In the U.S., the recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is 250 mg every four weeks or every eight weeks.1

Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well-controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans. We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative. Through Lilly Support Services™ for EBGLYSS®, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients.

INDICATION AND SAFETY SUMMARY  
EBGLYSS® (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well-controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.

It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

Before using
Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:

Have a parasitic (helminth) infection. Are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with EBGLYSS. Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy. Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Possible side effects
EBGLYSS can cause serious side effects, including:

Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing swelling of the face, lips, mouth, tongue or throat hives itching fainting, dizziness, feeling lightheaded skin rash cramps in your stomach area (abdomen) Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. The most common side effects of EBGLYSS include:

eye and eyelid inflammation, including redness, swelling, and itching injection site reactions shingles (herpes zoster) These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How to take

See the detailed "Instructions for Use" that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes. Use EBGLYSS exactly as prescribed by your healthcare provider. EBGLYSS is given as an injection under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver. If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time. Learn more
EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com

This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you.

LK CON BS AD APP

EBGLYSS®, its delivery device base, and Lilly Support Services™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, they are the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements  
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about EBGLYSS (lebrikizumab-lbkz) as a treatment for patients with moderate-to-severe atopic dermatitis and the timeline for future readouts, presentations, and other milestones relating to EBGLYSS and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date or that EBGLYSS will receive additional regulatory approvals, or that it will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1 EBGLYSS. Prescribing Information. Lilly USA, LLC.
2 Silverberg J, et al. Lebrikizumab every 8 weeks as maintenance dose provides long-lasting response in patients with moderate-to-severe atopic dermatitis. Presented at: Fall Clinical Dermatology Conference; 2025.
3 Okragly A, et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatology and Therapy. Published online June 13, 2023. doi:10.1007/s13555-023-00947-7
4 Ultsch M, et al. Structural basis of signaling blockade by an interleukin-13 antibody lebrikizumab. Journal of Molecular Biology. 2013;425(8):1330-1339. doi:10.1016/j.jmb.2013.01.024

CMAT-27572 06/2026 © Lilly USA, LLC 2026. All rights reserved.

SOURCE Eli Lilly and Company

SummaryCompaniesTolerability remains key challenge, with most GLP-1 drugs causing significant side effectsLilly's retatrutide trial data confirms highest weight loss among current and pipeline drugsShares of Lilly rose after ADA conference, while Novo, Roche, Pfizer and Zealand fellNEW YORK/LONDON, June 10 (Reuters) - Eli Lilly (LLY.N), opens new tab has solidified its leading position in the booming market for obesity drugs ahead of a wave ​of possible new entrants to the space.

Lilly last weekend presented more detailed data from trials of its once-weekly injection retatrutide, confirming to investors and clinicians that its ‌experimental drug is likely to offer the greatest weight loss prospects of any medicines currently on the market or in the pipeline.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Roche (ROPC.S), opens new tab, AstraZeneca (AZN.L), opens new tab, Pfizer (PFE.N), opens new tab and others also presented fresh data that turned the American Diabetes Association meeting in New Orleans into more of a weight-loss conference, and raised the prospect of greater choice in a fast-growing market so far dominated by Indianapolis-based Lilly and Denmark's Novo Nordisk (NOVOb.CO), opens new tab.

Drugs presented by Novo, Roche and others are "on par" with ​current ones in terms of weight loss and side effects but cannot compete with Lilly's next-generation products, said RBC analyst Trung Huynh.

"The bar is just moving higher and higher," ​he said in a phone interview.

Eli Lilly shares closed 1.6% higher on Monday, the first trading day following the ADA conference. Shares of Novo ⁠fell 4.2% and Roche, Pfizer and Zealand Pharma (ZELA.CO), opens new tab, which is developing obesity injection petrelintide with Roche, all lost ground.

DOMINATING MARKET SEGMENTSWith prices falling and a growing number of weight-loss options on ​the horizon, some companies may set their sights on certain segments of the patient population.

Roche says patients seeking maximum weight loss may choose more potent therapies such as its experimental dual-acting enicepatide, while others may ​choose a trade off of more modest weight loss and fewer side effects that could be easier to stay on longer term.

"We have to look at the entire gamut of people living with obesity because it's so heterogeneous, it's complex, and there is going to be segmentation," said Manu Chakravarthy, who oversees cardiovascular, renal and metabolism product development at Roche.

In data presented at ADA, Roche said patients lost 22.7% of their bodyweight in a mid-stage ​trial of enicepatide with a gastrointestinal side effect profile similar to existing GLP-1s.

Chakravarthy said once-weekly injection petrelintide, an amylin-based drug, has a "placebo-like" tolerability profile that could give it an edge.

AstraZeneca said it sees ​its oral GLP-1 elecoglipron as the foundation of a broader obesity strategy that could include combinations with its medicines for type 2 diabetes and kidney and heart disease.

For both Novo and Lilly, the strategy remains ‌to cover the ⁠waterfront with multiple options for a large, diverse market.

"Rather than taking a one-size-fits-all approach, we aim to match the right medicine to the right patient," said Novo Chief Medical Officer Filip Knop.

Lilly also says it expects to provide the broadest set of options for people living with overweight and obesity. Kenneth Custer, president of Lilly Cardiometabolic Health, said patients "may even choose to start on one Lilly medicine and move to another Lilly medicine."

FEWER SIDE EFFECTS HARD TO COME BYWhile companies push weight-loss boundaries, the area with the greatest room for improvement is the daunting side effect profile of ​some of these medicines. The therapies that rely ​on the GLP-1 and GIP hormones tend ⁠to cause stomach issues such as nausea and vomiting.

Discontinuation rates in clinical trials due to side effects has become a closely watched data point by Wall Street. Studies put the percentage of patients who experience nausea at about 40% for some drugs.

Pfizer said its experimental drug berobenatide has a similar ​side effect profile to Novo's Wegovy. The drug could become the first GLP-1 to be offered as a monthly shot.

"Tolerability really is ​the unmet medical need at ⁠the moment," said HSBC analyst Rajesh Kumar.

"As long as you're getting over 12%, 15% weight loss, most people don't need more than 20%. You want something that is competitive on efficacy, good tolerability, and people can take on a regular basis."

Therapies that don't prompt GI side effects are likely a ways off. Lilly, Pfizer, AbbVie (ABBV.N), opens new tab, Astrazeneca and Roche with Zealand are all working on amylin-based drugs.

Novo's Cagrisema, which combines semaglutide ⁠with an ​amylin drug and was seen as a potential Wegovy successor, fell short on weight-loss expectations.

Lilly's experimental eloralintide also aims to ​fill that improved tolerability need.

"What we've seen with the amylin class so far is that it seems to really stand out" on tolerability, Custer said. "We want to make sure for the 5% to 10% of patients who would like something ​else, that we have an option to give them."

Reporting by Chris Prentice and Michael Erman in New York and Maggie Fick and Bhanvi Satija in London; Editing by Caroline Humer and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Chris Prentice is on assignment with the U.S. Healthcare and Pharma team. She has also reported on financial crime, commodities markets and trade policy. Her work, solo and in collaboration with colleagues, has been honored with Gerald Loeb, Society for Advancing Business Editing and Writing, and New York Newswomen's Club awards.

Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year award in the Beat Coverage of the Year category. Since November 2023, she has also been participating in Reuters coverage related to the Israel-Hamas war. Previously based in Nairobi and Cairo for Reuters and in Lagos for the Financial Times, Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in South Sudan.

© Arsenii Palivoda / Shutterstock.com

I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one. They each do something I cannot replicate by being clever.

Why the buy button stays active on NVIDIA NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) is the one position where I have stopped pretending I can time it. Q1 FY27 revenue came in at $81.61 billion, up 85.23% year over year, with non-GAAP EPS of $1.87 against a $1.7738 estimate. Free cash flow alone was $48.55 billion in a single quarter. Full year FY26 free cash flow reached $96.58 billion. That is the cash machine I am buying.

The capital return shift sealed it for me. The quarterly dividend went from $0.01 to $0.25, a fresh $80 billion buyback authorization landed on top of $38.5 billion remaining, and roughly $20 billion came back to shareholders in Q1.

Jensen Huang framed the cycle plainly: “The buildout of AI factories, the largest infrastructure expansion in human history, is accelerating at extraordinary speed.” Supply commitments of $119 billion tell me management sees the demand the same way I do.

The honest risk is China. The Q2 guide assumes zero Data Center compute revenue from China, and no H20 shipped last quarter. I respect it. I also note that the company is guiding $91 billion for Q2 anyway. The shares are up 12.01% year to date and 47.42% over one year, and the earnings power is growing faster than the multiple.

Eli Lilly is the franchise I keep underestimating Eli Lilly (NYSE:LLY) keeps proving me too cautious. Q1 2026 revenue was $19.80 billion, up 55.5% YoY, with EPS of $8.55 against a $6.79 estimate. Mounjaro alone delivered $8.66 billion (125% YoY growth) and Zepbound added $4.16 billion (80% YoY). Full year guidance was raised to $82 to $85 billion in revenue and $35.5 to $37 in non-GAAP EPS.

Foundayo, the first oral GLP-1 that can be taken any time of day without food or water restrictions, is the catalyst I keep coming back to. CEO David Ricks said “Foundayo will meaningfully expand the number of people who can benefit from GLP-1s.”

The honest risk is pricing: realized prices fell 13% in the quarter, with China’s NRDL inclusion adding pressure. Volume grew 65%, which is the answer to that risk.

Johnson & Johnson is the ballast Johnson & Johnson (NYSE:JNJ) is the one I would buy first, because it is the position that lets me sleep. The quarterly dividend was raised 3.1% to $1.34 per share, the 64th consecutive year of increases.

Q1 2026 revenue rose 9.9% YoY to $24.062 billion, adjusted EPS was $2.70, and full year 2026 guidance was lifted to $100.3 to $101.3 billion in revenue and $11.45 to $11.65 in adjusted EPS. DARZALEX grew 22.5%, TREMFYA grew 68.3%, and 2025 free cash flow was $19.7 billion.

The honest risk is STELARA, which fell 59.7% to $656 million on biosimilar erosion. TREMFYA and the oncology stack are absorbing that hit in real time, and the dividend record speaks louder to me than the biosimilar headline.

The forward conviction Compounding cash flow at NVIDIA, a generational franchise at Lilly, and 64 years of paid dividends at Johnson & Johnson: that is how I would rebuild a portfolio, and that is why my buy button is still warm.

Andrew Arons discusses summer market equity expectations and stocks he's watching in the current environment. He points to Micron (MU) as one that has much more room to run even after a stellar year-long rally, pointing to robust AI memory demand backing the trade.

© Caroline Ruda / Shutterstock.com

Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance.

Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very different stories about who is winning it.

Mounjaro Roars. Wegovy Holds The Line. Lilly’s quarter was carried by tirzepatide. Mounjaro brought in $8.66 billion, up 125% year over year, helped by international launches and China’s NRDL inclusion. Zepbound added $4.16 billion, up 80%.

Volume jumped 65% while realized prices fell 13%, a deliberate trade per CEO David Ricks. The FDA approved Foundayo (orforglipron), the only GLP-1 pill with no food or water restrictions.

Q1 2026 Driver Eli Lilly Novo Nordisk Revenue trajectory +55.5% YoY -4% adjusted at CER Lead obesity product Zepbound, +80% Wegovy injectable, +12% Oral GLP-1 entry Foundayo, no food/water rules Wegovy pill, first to market 2026 guidance move Raised to $82B-$85B Still -4% to -12% CER Novo’s franchise is splitting. Wegovy injectable grew 12% to $18.24 billion, and the new Wegovy pill, launched January 5, 2026, booked $2.26 billion with over 1 million patients. Ozempic slid 8%, Rybelsus dropped 15%, and US sales fell 11%. CEO Mike Doustdar leaned on the pill story because the rest of the portfolio is shrinking.

Broadening Out vs. Battening Down Lilly is buying growth in four directions, announcing acquisitions of Orna, Centessa, Kelonia, and Ajax across cell therapy, sleep-wake biology, in vivo CAR-T, and myelofibrosis. Ebglyss jumped 141% and Jaypirka rose 79%. International revenue climbed 81%, suggesting the global ramp is only starting.

Novo is consolidating around semaglutide and cagrilintide, restructuring costs, and absorbing the Most Favoured Nations pricing deal. The CagriSema REDEFINE 4 trial missed its primary endpoint, even with 23% weight loss, dents the next-generation thesis. A planned 50% Wegovy list price cut in January 2027 will pressure margins.

What I Want To See Next I will watch how quickly Foundayo scales relative to Novo’s oral semaglutide, since the pill war is now the obesity story. Lilly’s retatrutide Phase 3 readouts and the Taltz plus Zepbound psoriasis combo could open new categories.

For Novo, the question is whether Medicare Part D coverage starting July 1, 2026 can offset price cuts coming six months later. Retail mood reflects the split: LLY sentiment turned very bullish on Reddit in early June, while NVO drifted to bearish.

Why I Lean Toward Lilly, But Won’t Write Off Novo Lilly is the cleaner business. Revenue growth of 55.5%, a guidance raise to $35.5-$37 in non-GAAP EPS, and a stock up 48.98% over the past year reflect offense-mode execution. The valuation prices in a lot, so any Foundayo stumble would sting.

Novo interests me as a turnaround. Shares are down 41.53% over a year and 14.22% year to date, the Wegovy pill is working, and gross margin sits at 81%. Investors weighing the name will need to weigh 2027 price cuts and patent expirations against the turnaround setup. For now, the accelerating franchise looks like the cleaner story, with Novo worth revisiting once the MFN pricing math is digested.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Eli Lilly (LLY - Free Report) Indianapolis, IN-based Eli Lilly and Company, one of the world’s largest pharmaceutical companies, boasts a diversified product profile, including a solid lineup of new successful drugs. It also has a dependable pipeline in areas like obesity, diabetes and Alzheimer’s.

LLY is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. LLY has a Growth Style Score of A, forecasting year-over-year earnings growth of 47.3% for the current fiscal year.

Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.93 to $35.67 per share. LLY also boasts an average earnings surprise of +14.5%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, LLY should be on investors' short list.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 31, 2026 to holders of record on June 26, 2026.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

SOURCE Danaher Corporation

Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

It has been about a month since the last earnings report for Danaher (DHR - Free Report) . Shares have lost about 7% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Danaher due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Danaher Corporation before we dive into how investors and analysts have reacted as of late.

Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Up Y/YDanaher’s first-quarter 2026 adjusted earnings of $2.06 per share beat the Zacks Consensus Estimate of $1.95. The bottom line increased 9.6% year over year.

Danaher reported net sales of $5.95 billion, which missed the consensus estimate of $5.99 billion. However, the metric increased 3.5% year over year. The quarter reflected continued strength in the bioprocessing business and better-than-expected performance in the Life Sciences segment.

DHR’s core sales increased 0.5% year over year in the quarter. Foreign-currency translations had a positive impact of 3%.

Segmental DiscussionRevenues from the Life Sciences segment totaled $1.74 billion, up 3.5% year over year. The Zacks Consensus Estimate for the segment’s revenues was pegged at $1.73 billion. Core sales increased 0.5% year over year. Foreign-currency translations had a positive impact of 3%. Operating profit was $225 million compared with $205 million reported in the year-ago quarter.

Revenues from the Diagnostics segment totaled $2.42 billion, down 1.5% year over year. The Zacks Consensus Estimate for the segment’s revenues was pegged at $2.47 billion. Core sales declined 4.0% while foreign currency had a positive impact of 2.5% on sales. Operating profit was $674 million, down 6.1% on a year-over-year basis.

Revenues from the Biotechnology segment totaled $1.80 billion, up 11.5% year over year. The Zacks Consensus Estimate for the segment’s revenues was pegged at $1.79 billion. Core sales increased 7% year over year and foreign-currency translations had a positive impact of 4.5%. Operating profit was $534 million, up 21.1% year over year.

Danaher’s Margin ProfileIn the first quarter, Danaher’s cost of sales increased 5.8% year over year to $2.36 billion. Gross profit of $3.59 billion increased 2.3% year over year. The gross margin was 60.3% compared with 61.2% in the year-ago quarter.

Selling, general and administrative expenses were flat at $1.86 billion. Research and development expenses were $387 million, up 2.1% year over year.

Danaher’s operating profit increased 5.5% year over year to $1.34 billion. Operating margin increased to 22.6% from 22.2% in the year-ago quarter.

Balance Sheet & Cash FlowExiting the first quarter, it had cash and equivalents of $5.70 billion compared with $4.62 billion at 2025-end. Long-term debt was $17.6 billion at the end of the quarter compared with $18.4 billion at the end of December 2025.

Danaher generated net cash of $1.32 billion from operating activities in the first three months of 2026 compared with $1.30 billion in the previous year’s comparable period. Capital expenditures totaled $237 million in the same period, down 3.3% year over year. Adjusted free cash flow increased 2.4% year over year to $1.09 billion in the first three months of 2026.

In the same period, it paid out dividends of $226 million, up 16.5% on a year-over-year basis.

Danaher Raises 2026 EPS ViewFor the second quarter of 2026, Danaher expects adjusted core sales to increase in the low single digits on a year-over-year basis.

The metric is anticipated to increase 3-6% on a year-over-year basis in 2026. The company expects adjusted earnings to be $8.35-$8.55 per share compared with $8.35-$8.50 expected earlier.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

VGM ScoresAt this time, Danaher has a subpar Growth Score of D, a grade with the same score on the momentum front. Following the exact same course, the stock has a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Danaher has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

On May 28, 2026, Danaher Corp DHR shares rose 4.3%, reflecting a positive shift in market sentiment. The stock is currently trading at $180.63, within a 52-week range of $160.93 to $242.80.

GF Value™ verdict: Current price $180.63 vs GF Value™ $236.05, indicating a 23.5% upside. GF Score™ of 77/100 suggests that DHR is above average in terms of overall quality and potential for long-term returns. Notable signal: Financial strength rated at 7/10, indicating a solid financial position. Is DHR Overvalued or Undervalued? Danaher Corp's current price of $180.63 is significantly below the GF Value™ estimate of $236.05, which implies that the stock is undervalued by approximately 23.5%. This margin of safety presents an opportunity for investors who may seek to capitalize on the stock's potential upside. According to the GF Valuation label, Danaher is classified as modestly undervalued. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the undervaluation presents a potential opportunity, it is essential to consider market conditions and company-specific factors that may impact future performance. The stock has seen a year-to-date decline of 20.9%, which raises questions about its short-term momentum despite the current valuation metrics pointing to a favorable long-term outlook.

How Does DHR's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 34.9x 35.7x (5-Year Median) Forward P/E 21.4x N/A The current P/E (TTM) of 34.9x is slightly below the 5-year median P/E of 35.7x, indicating that the stock is trading at a valuation that is consistent with its historical performance. This analysis aligns with the GF Value™ verdict of being undervalued, reinforcing the notion that the stock may offer a favorable entry point at its current price.

What Does DHR's GF Score™ Tell Us? Metric Rating GF Score™ 77/100 Financial Strength 7/10 Profitability 7/10 Growth 5/10 Valuation 8/10 Momentum 4/10 The GF Score™ of 77/100 indicates that Danaher Corp possesses strong financial strength and profitability, both rated at 7/10. However, growth is a weaker area with a score of 5/10, while valuation ranks favorably at 8/10. The momentum rank of 4/10 suggests that the stock may not be experiencing significant positive price movements in the short term, which could be a consideration for investors focused on trend following.

What Are Insiders Doing with DHR Stock? In the last three months, insider activity has shown that insiders sold approximately $0.2 million worth of shares, with no reported purchases. This selling may indicate a lack of confidence among insiders regarding the stock's immediate prospects, which could be interpreted as a cautious signal. Nonetheless, such activity should be viewed in the context of overall market conditions and individual insider strategies.

What This Means for Investors Based on the current analysis, Danaher Corp DHR is considered to be undervalued according to GF Value™, presenting a potential opportunity for long-term investors. However, the recent negative price momentum and insider selling should be taken into account when evaluating the stock.

For the complete analysis, visit the Danaher Corp DHR stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is DHR's GF Score™?

DHR's GF Score™ is 77/100, indicating above-average quality and potential for long-term returns based on various financial metrics.

Is DHR overvalued or undervalued?

DHR is considered undervalued with a GF Value™ estimate of $236.05, suggesting significant upside potential from the current price of $180.63.

What is DHR's P/E ratio?

DHR's P/E (TTM) is 34.9x, which is slightly below its 5-year median of 35.7x, indicating the stock is trading at a comparable historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

MARLBOROUGH, Mass.--(BUSINESS WIRE)--At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, introduced platform-wide advancements across its accurate mass ZenoTOF line. The updates include new SCIEX OS 5.0 software features, broader front-end compatibility, and forward-looking software collaborations designed to help omics researchers solve complex biological questions. This connected environment reduces workflow complexity, while enabling deeper, more actionable insights from a single, dynamic platform.

SCIEX OS 5.0 software introduces new features including Central Metrics Tracker, Central Monitoring, Reporter Template Creator, an AI enabled “helpme” function, and AI enabled Calculated Columns. Additional ZenoTOF line specific advancements include:

ZT Scan DIA 3.0 combines the completeness of data-independent acquisition with narrower Q1 isolation windows so researchers can balance selectivity, sensitivity, and throughput based on the requirements of the experiment. This technology underpins scalable proteomics and robust metabolomics, reducing workflow complexity and expanding the range of applications a single platform can address. With enhanced sensitivity mode on, the ZenoTOF 8600 system has demonstrated significant gains for low-input proteomics workflows with nanoflow, where improvements range from approximately 10% to 40% gains in both identification and quantitation. Expanded front-end compatibility boosts the flexibility of the ZenoTOF line.

Echo® MS+ system integration with the ZenoTOF 8600 system is the industry’s highest-throughput accurate mass platform, sampling at up to 1 sample per second. It delivers enhanced sensitivity for high-throughput screening, making it a foundational screening technology to accelerate early discovery, reduce complexity and consumable costs. HDX-MS by Trajan Scientific and Medical brings deep automation expertise and comprehensive data processing, unlocking deeper insights into protein structure and binding. These bookends complement EAD on the ZenoTOF line to deliver an integrated end-to-end solution for routine high-sensitivity, zero-scrambling, amino-acid residue resolved HDX-MS. New source enhancements deliver seamless compatibility between Evosep, IonOpticks, and the ZenoTOF line. Researchers can now fully leverage Whisper Zoom methods—bringing together high sensitivity, robustness, and throughput in a unified SCIEX-based platform to accelerate next-generation proteomics analyses. In addition, an agreement between SCIEX and IonOpticks plans to expand access to advanced liquid chromatography solutions for the proteomics community, including Aurora XS columns. Key collaborations across leading software platforms enable researchers to operate within the workflows they already use and trust.

A key collaboration brings BSI’s advanced AI-based proteomic PEAKS software data processing across the ZenoTOF line. It enables researchers to identify, quantify, and validate biomarkers in a single solution, and eliminates the traditional fragmentation between discovery and targeted quantitation, reducing complexity and improving reproducibility for translational research. MS-Dial becomes one of the pioneer collaborators translating ZT Scan DIA 3.0 measurements into life science answers. Customers can discover new biomarkers using this trusted life-sciences software package that profiles metabolomics and lipidomics. Collaboration with MZIO brings SCIEX data compatibility into mzmine, allowing users to integrate SCIEX into existing metabolomics and small molecule pipelines that support scalable data processing, advanced feature extraction, and downstream analysis across diverse MS workflows. “Ultimately, we are not just delivering incremental performance — but a step change in how researchers can move across the omics continuum. This is just the beginning. Our commitment is simple - continuous innovation in this dynamic platform delivers for customers, across workflows,” says Jose Castro-Perez, Vice President of Product Management at SCIEX.

Learn more about the ZenoTOF line unlock at https://sciex.com/products/mass-spectrometers/qtof-systems/8600-system.

ABOUT SCIEX

SCIEX, a Danaher company and leader in life science analytical technologies, empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust.

Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, and Instagram.​

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2026 DH Tech. Dev. Pte. Ltd. MKT-38539-A.